REGNbenzinga

Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $775

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 13, 2022 by benzinga

    Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $775 | REGN Stock News | Candlesense